IL117371A - Process for the isolation of galanthamine galanthamine produced thereby and pharmaceutical compositions containing the same - Google Patents

Process for the isolation of galanthamine galanthamine produced thereby and pharmaceutical compositions containing the same

Info

Publication number
IL117371A
IL117371A IL11737196A IL11737196A IL117371A IL 117371 A IL117371 A IL 117371A IL 11737196 A IL11737196 A IL 11737196A IL 11737196 A IL11737196 A IL 11737196A IL 117371 A IL117371 A IL 117371A
Authority
IL
Israel
Prior art keywords
galanthamine
isolation
produced
same
pharmaceutical compositions
Prior art date
Application number
IL11737196A
Other languages
English (en)
Other versions
IL117371A0 (en
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of IL117371A0 publication Critical patent/IL117371A0/xx
Publication of IL117371A publication Critical patent/IL117371A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Extraction Or Liquid Replacement (AREA)
IL11737196A 1995-03-17 1996-03-05 Process for the isolation of galanthamine galanthamine produced thereby and pharmaceutical compositions containing the same IL117371A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19509663A DE19509663A1 (de) 1995-03-17 1995-03-17 Verfahren zur Isolierung von Galanthamin

Publications (2)

Publication Number Publication Date
IL117371A0 IL117371A0 (en) 1996-07-23
IL117371A true IL117371A (en) 2000-01-31

Family

ID=7756925

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11737196A IL117371A (en) 1995-03-17 1996-03-05 Process for the isolation of galanthamine galanthamine produced thereby and pharmaceutical compositions containing the same

Country Status (23)

Country Link
US (5) US5877172A (fr)
EP (2) EP0815112B1 (fr)
JP (1) JP3863180B2 (fr)
KR (1) KR100427093B1 (fr)
CN (1) CN1088460C (fr)
AT (2) ATE247473T1 (fr)
AU (1) AU707203B2 (fr)
CA (1) CA2215351C (fr)
CZ (1) CZ294722B6 (fr)
DE (3) DE19509663A1 (fr)
DK (2) DK1095656T3 (fr)
ES (2) ES2206356T3 (fr)
HU (1) HU225267B1 (fr)
IL (1) IL117371A (fr)
MY (1) MY114698A (fr)
NO (1) NO316380B1 (fr)
NZ (1) NZ304008A (fr)
PL (1) PL184238B1 (fr)
PT (2) PT815112E (fr)
SI (1) SI1095656T1 (fr)
SK (1) SK283861B6 (fr)
WO (1) WO1996029332A1 (fr)
ZA (1) ZA962140B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
EP1150695B1 (fr) * 1999-01-11 2007-02-28 Atanas Russinov Djananov Complement alimentaire vegetal servant a ameliorer la resistance musculaire et l'endurance d'athletes
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
GB9909469D0 (en) * 1999-04-23 1999-06-23 Wilkinson John A Insectidal composition
US6426097B2 (en) * 2000-01-28 2002-07-30 Herbaceuticals Inc. Herbal supplement for cognitive related impairment due to estrogen loss
CA2310926C (fr) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. Utilisation de la galantamine pour le traitement du comportement neuropsychiatrique associe a la maladie d'alzheimer
DE10119862A1 (de) 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
AU2002366555A1 (en) * 2001-12-10 2003-06-23 Washington University Diagnostic for early stage alzheimer's disease
US20040067934A1 (en) * 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU2004216360B2 (en) * 2003-02-27 2009-09-17 Eisai R & D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2551946A1 (fr) * 2003-12-31 2005-07-21 Actavis Group Hf Formulations de galantamine
WO2005065662A1 (fr) * 2003-12-31 2005-07-21 Actavis Group Hf Formulations solides d'administration de galantamine
WO2006013546A2 (fr) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Procede de preparation de galantamine pure
FR2879599B1 (fr) * 2004-12-16 2007-03-23 Centre Nat Rech Scient Cnrse Utilisation de la chromatographie de partage centrifuge pour la purification de la galanthamine
ITMI20042413A1 (it) * 2004-12-17 2005-03-17 Indena Spa Processo per la preparazione di galantamina bromidrato
KR20070119641A (ko) * 2005-03-17 2007-12-20 아이박스 파마슈티컬스 에스.알.오. 생체 물질로부터 갈란타민을 단리하는 방법
WO2006124585A2 (fr) * 2005-05-13 2006-11-23 Alza Corporation Systeme d'administration de galantamine a couches multiples equipe d'une protection contre l ecoulement un flux de matiere de reservoir
CN1307180C (zh) * 2005-05-24 2007-03-28 天津大学 从石蒜或雪花莲属原料中提取加兰他敏的方法
EP1937226A2 (fr) * 2005-09-23 2008-07-02 Alza Corporation Systeme d'administration transdermique de galantamine
US7446352B2 (en) * 2006-03-09 2008-11-04 Tela Innovations, Inc. Dynamic array architecture
EP2039302A3 (fr) 2007-09-18 2009-06-10 Ethicon Endo-Surgery, Inc. Dispositifs pour prévenir un iléus post-opératoire
WO2010029554A1 (fr) 2008-09-11 2010-03-18 I.B.R. Israeli Biotechnology Research Ltd. Extraits de bulbe de leucojum et utilisation de ceux-ci
US8247405B2 (en) * 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
CN101602767B (zh) * 2009-05-26 2012-01-11 苏州派腾生物医药科技有限公司 一种加兰他敏的制备方法
DE102009040381A1 (de) 2009-09-07 2011-03-17 Kallimopoulos, Thomas, Dr. Verfahren zur Isolierung von Alkaloiden aus Pflanzen
CN101787028B (zh) * 2010-01-12 2012-01-04 恩施清江生物工程有限公司 一种从忽地笑中提取加兰他敏的方法
CN102050826B (zh) * 2010-12-21 2012-11-14 浙江工业大学 一种分离加兰他敏的方法
BG67337B1 (bg) 2018-05-23 2021-06-15 Софарма Ад Метод за получаване на пречистен галантамин хидробромид
CN117717558A (zh) * 2023-12-06 2024-03-19 艾威药业(珠海)有限公司 加兰他敏及其药学上可接受的盐在制备治疗眼部疾病的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1193061B (de) * 1961-12-20 1965-05-20 Vni Chimiko Pharmazewtitschesk Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
EP0584185B1 (fr) * 1991-05-14 1999-08-11 Ernir Snorrason Traitement des etats de fatigue a l'aide d'inhibiteurs de cholinesterase
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin

Also Published As

Publication number Publication date
US20020028802A1 (en) 2002-03-07
JP3863180B2 (ja) 2006-12-27
PL184238B1 (pl) 2002-09-30
PT1095656E (pt) 2004-01-30
EP1095656A2 (fr) 2001-05-02
DE59607450D1 (de) 2001-09-13
US6194404B1 (en) 2001-02-27
HU225267B1 (en) 2006-08-28
NO974119L (no) 1997-09-08
IL117371A0 (en) 1996-07-23
AU5108896A (en) 1996-10-08
SK123597A3 (en) 1998-02-04
DK1095656T3 (da) 2003-12-08
ES2162035T3 (es) 2001-12-16
MY114698A (en) 2002-12-31
CA2215351A1 (fr) 1996-09-26
CN1178533A (zh) 1998-04-08
KR19980703067A (ko) 1998-09-05
US20010001100A1 (en) 2001-05-10
EP1095656B1 (fr) 2003-08-20
US6617452B2 (en) 2003-09-09
JPH11505519A (ja) 1999-05-21
HUP9802234A2 (hu) 1999-02-01
SI1095656T1 (en) 2004-02-29
EP0815112A1 (fr) 1998-01-07
DK0815112T3 (da) 2001-11-12
EP0815112B1 (fr) 2001-08-08
AU707203B2 (en) 1999-07-08
ZA962140B (en) 1996-09-16
US5877172A (en) 1999-03-02
EP1095656A3 (fr) 2001-05-16
PT815112E (pt) 2002-01-30
ATE247473T1 (de) 2003-09-15
ES2206356T3 (es) 2004-05-16
DE19509663A1 (de) 1996-09-19
WO1996029332A1 (fr) 1996-09-26
CA2215351C (fr) 2005-01-11
MX9707015A (es) 1997-11-29
ATE203993T1 (de) 2001-08-15
NO974119D0 (no) 1997-09-08
CZ283597A3 (en) 1997-12-17
NO316380B1 (no) 2004-01-19
US20030012831A1 (en) 2003-01-16
US6573376B2 (en) 2003-06-03
HUP9802234A3 (en) 2000-03-28
NZ304008A (en) 1998-09-24
KR100427093B1 (ko) 2004-07-31
US6335328B2 (en) 2002-01-01
CZ294722B6 (cs) 2005-03-16
PL322463A1 (en) 1998-02-02
SK283861B6 (sk) 2004-03-02
CN1088460C (zh) 2002-07-31
DE59610680D1 (de) 2003-09-25

Similar Documents

Publication Publication Date Title
IL117371A0 (en) A process for the isolation of galanthamine galanthamine produced thereby and pharmaceutical compositions containing the same
HUT56137A (en) Process for rising overproduction of lysine in plants
HUP9603428A2 (en) Novel crystalmodification of cdch and process for producing it and pharmaceutical composition containing it
HUT59161A (en) Process for producing serine-protease inhibitors and pharmaceutical compositions containing them
HUT67178A (en) External preparations containing cyclosporin and process for production of them
HUT56538A (en) Process for producing biologically effective 19-nor-d vitamin compounds and pharmaceutical compositions comprising such compounds
EP0356484A4 (fr) Procede de preparation de produits derives de l'aloes.
AU3480689A (en) Process for treatment of water containing volatile and toxic compounds
HUT54384A (en) Process for producing enzyme-inhibitor dipeptide derivatives and pharmaceutical compositions containing them
IL74138A (en) 4,6,6a,7,8,12b-hexahydro-indolo(4,3-ab)phenanthridines,their production and pharmaceutical compositions containing them
FR2620726B1 (fr) Procede de preparation d'un extrait de jasmin et extrait obtenu
MY104051A (en) Method for stimulating plant growth using synthetically produced 9-beta-l(+) adenosine.
HUT65923A (en) Process for making a composition containing extract of herbs and cosmetics containing the composition
CS689890A3 (en) Massage ointment containing plant extracts and process for preparingthereof
HUT73638A (en) Process for extracting organic components of natural water and producing pharmaceutical compositions comprising this extract
FR2686019B1 (fr) Composition de seve et d'extrait vegetal.
FR2714053B1 (fr) Procédé d'extraction et d'isolement de la 10-désacétylbaccatine III.
PL289404A1 (en) Method of isolating alkaloids as individual compounds or in groups from materials of plant origin
IL98448A0 (en) Method and compositions for treating hiv-type 1 infection containing a dipeptide derivative
IL78820A (en) Pharmaceutical and cosmetic compositions comprising lycopersicon plants'extract and process for extraction of tomatine
HU9000161D0 (en) Process for manufacturing of pharmaceutical compositions suitable to treatment and prevention of atherosclerosis
HU9303434D0 (en) Process for production of pharmaceutical components and preparations containing said compounds
HUT61512A (en) Liquid fertilizer composition of high concentration and process for producing same
HUT44166A (en) Medicinal plant extract containing also bioactive component of mineral origin, process for production thereof and cosmetical compositions containing them
HUT65800A (en) Process for making composition containing herb extract acting on bile and liver

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired